When an FDA panel held her company’s future in the balance, UroGen Pharma CEO Liz Barrett refused to fold, even with the odds stacked, a plunging stock, and one vote deciding it all.

PODCAST TEAM

Producer and Director: Devon Leaver

Editor: Dominique Guerra

Production Coordinator: YingYu Lin

Production Support: Annabelle Chan

Story Consultants: Partner & Research Analyst Tony Nguyen, and Chief Corporate Finance Officer, Chris Seiter.

Featuring: Liz Barrett, President & CEO of UroGen Pharma, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 - Introduction

00:54 – Liz Barrett’s pharma journey

03:26 - UroGen: the product and the pipeline

08:31 - The FDA vote on UroGen

15:07 - UroGen and RTW’s relationship

18:42 - Liz Barrett’s leadership style

22:40 - Outro

DISCLAIMER

This interview was given by Liz Barrett, President & CEO of UroGen Pharma, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments, LP. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.

The Split Vote: UroGen and the FDA

The RTW Podcast